Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) shares traded up 3.9% on Friday . The stock traded as high as $10.70 and last traded at $10.56, with a volume of 4,371,913 shares. The stock had previously closed at $10.16.

Several analysts have recently commented on ARIA shares. Cowen and Company reiterated an “outperform” rating and issued a $10.00 price target on shares of Ariad Pharmaceuticals in a research report on Sunday, July 31st. Barclays PLC increased their price target on shares of Ariad Pharmaceuticals from $8.00 to $9.00 and gave the company an “underweight” rating in a research report on Friday, July 29th. Jefferies Group reiterated a “buy” rating and issued a $13.00 price target on shares of Ariad Pharmaceuticals in a research report on Friday, July 29th. JMP Securities reiterated a “buy” rating on shares of Ariad Pharmaceuticals in a research report on Monday, June 6th. Finally, William Blair reiterated a “buy” rating and issued a $10.00 price target on shares of Ariad Pharmaceuticals in a research report on Tuesday, May 24th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. Ariad Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $9.19.

The stock’s market cap is $2.04 billion. The stock has a 50 day moving average price of $8.31 and a 200 day moving average price of $7.10.

Ariad Pharmaceuticals (NASDAQ:ARIA) last released its quarterly earnings results on Thursday, July 28th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.70. The company had revenue of $65.30 million for the quarter, compared to the consensus estimate of $60.64 million. The firm’s quarterly revenue was up 133.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.28) earnings per share. Equities research analysts forecast that Ariad Pharmaceuticals Inc. will post ($0.08) EPS for the current year.

In other Ariad Pharmaceuticals news, insider Timothy P. Clackson sold 18,286 shares of the business’s stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $8.11, for a total transaction of $148,299.46. Following the sale, the insider now directly owns 248,208 shares in the company, valued at approximately $2,012,966.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Timothy P. Clackson sold 17,762 shares of the business’s stock in a transaction dated Monday, May 23rd. The stock was sold at an average price of $8.08, for a total transaction of $143,516.96. Following the sale, the insider now owns 288,741 shares in the company, valued at $2,333,027.28. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Ariad Pharmaceuticals stock. Rhumbline Advisers increased its position in Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) by 7.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 174,193 shares of the pharmaceutical company’s stock after buying an additional 12,560 shares during the period. Rhumbline Advisers owned about 0.09% of Ariad Pharmaceuticals worth $1,089,000 at the end of the most recent quarter.

ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.